home / stock / bcab / bcab news

BCAB News and Press, BioAtla Inc.

Stock Information
Company Name: BioAtla Inc.
Stock Symbol: BCAB
Market: NASDAQ
Website: bioatla.com
Menu
BCAB BCAB Quote BCAB Short BCAB News BCAB Articles BCAB Message Board
Get BCAB Alerts

News, Short Squeeze, Breakout and More Instantly...
BCAB - BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day ar...
BCAB - BioAtla to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...

BCAB - LIDR, HOOK and BCAB among mid-day movers

2024-05-24 12:58:09 ET More on BioAtla, HOOKIPA Pharma, etc. BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript AEye, Inc. (LIDR) Q1 2024 Earnings Call Transcript BioAtla: A Buried ADC Concern Gets Some New Life In 2024 AEye Q1 2024 Earnings Preview ...

BCAB - BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a monotherapy or in combination with PD1 are associated with manageable safety w...
BCAB - BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

2024-05-14 20:35:23 ET BioAtla, Inc. (BCAB) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Bruce Mackle – LifeSci Advisors Jay Short – Chairman, Chief Executive Officer and Co-Founder Eric Sievers – Chief Medica...

BCAB - BioAtla GAAP EPS of -$0.48 beats by $0.06

2024-05-14 16:13:18 ET More on BioAtla BioAtla: A Buried ADC Concern Gets Some New Life In 2024 BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioAtla Historical earnings data for BioAtla Financial informa...

BCAB - BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 Evalstotug (CTLA-4 antibody) Phase 1 stud...
BCAB - BioAtla to Participate in the Citizens JMP Life Sciences Conference

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...

BCAB - BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference cal...

BCAB - BioAtla announces FDA clearance of ind application for its treatment of multiple tumors

2024-05-06 09:17:28 ET More on BioAtla BioAtla: A Buried ADC Concern Gets Some New Life In 2024 BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioAtla Historical earnings data for BioAtla Financial informa...
Next 10